Details for New Drug Application (NDA): 200677

✉ Email this page to a colleague

NDA 200677 describes SIGNIFOR, which is a drug marketed by Recordati Rare and is included in two NDAs. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the SIGNIFOR profile page.

The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

Summary for 200677

Tradename:	SIGNIFOR
Applicant:	Recordati Rare
Ingredient:	pasireotide diaspartate
Patents:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 200677

Generic Entry Date for 200677^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 200677

Mechanism of Action	Somatostatin Receptor Agonists

Suppliers and Packaging for NDA: 200677

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677	NDA	Recordati Rare Diseases, Inc.	55292-131	55292-131-60	60 PACKAGE in 1 BOX (55292-131-60) / 6 AMPULE in 1 PACKAGE (55292-131-06) / 1 mL in 1 AMPULE (55292-131-01)
SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677	NDA	Recordati Rare Diseases, Inc.	55292-132	55292-132-60	60 PACKAGE in 1 BOX (55292-132-60) / 6 AMPULE in 1 PACKAGE (55292-132-06) / 1 mL in 1 AMPULE (55292-132-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)
Approval Date:	Dec 14, 2012	TE:		RLD:	Yes
Patent:	⤷ Sign Up	Patent Expiration:	Dec 14, 2026	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	⤷ Sign Up	Patent Expiration:	Dec 27, 2025	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)
Approval Date:	Dec 14, 2012	TE:		RLD:	Yes
Patent:	⤷ Sign Up	Patent Expiration:	Dec 14, 2026	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 200677

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Recordati Rare	SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677-001	Dec 14, 2012	⤷ Sign Up	⤷ Sign Up
Recordati Rare	SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677-003	Dec 14, 2012	⤷ Sign Up	⤷ Sign Up
Recordati Rare	SIGNIFOR	pasireotide diaspartate	SOLUTION;SUBCUTANEOUS	200677-002	Dec 14, 2012	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.